Earle Burgess: Bipolar androgen therapy for advanced prostate cancer

Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared on LinkedIn:

“Bipolar androgen therapy (BAT) for advanced prostate cancer: I am an advocate in the appropriate patient setting based on the TRANSFORMER study.

TRANSFORMER results and protocol.
Unfortunately we don’t know in advance which patients are most likely to benefit from using BAT.

Data presented from the TRANSFORMER study at ASCO24 suggest patients whose tumors contain an androgen receptor (AR) gene alteration may be the group most likely to benefit from BAT.

‘TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer‘ | Journal of Clinical Oncology

Authors: Samuel R Denmeade, Hao Wang, Neeraj Agarwal, David C Smith, Michael T Schweizer, Mark N Stein, Vasileios Assikis, Przemyslaw W Twardowski, Thomas W Flaig, Russell Z Szmulewitz, Jeffrey M Holzbeierlein, Ralph J Hauke, Guru Sonpavde, Jorge A Garcia, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J Paller, Michael A Carducci, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis.”

Source: Earle Burgess/LinkedIn